All AmerisourceBergen articles
Three major drug distributors and drugmaker Johnson & Johnson reached a proposed $26 billion multistate agreement for their alleged roles in fueling the nationwide opioid epidemic. The settlement imparts compliance lessons on the pharmaceutical industry at large.
False Claims Act recoveries related to healthcare fraud in fiscal year 2018 offer key insight into the best practices the government expects to ensure compliance with federal healthcare laws.
AmerisourceBergen and its subsidiaries have agreed to pay $625 million to resolve its civil liability to the United States under the False Claims Act for causing false claims for the drugs it repackaged to be submitted to federal health care programs.